ARROWHEAD PHARMACEUTICALS, INC.
Arrowhead Pharmaceuticals develops RNA interference medicines designed to silence disease-causing genes. Its TRiM platform uses RNA triggers and targeted delivery to develop therapies for diseases across multiple areas. The company’s pipeline includes candidates for lipid disorders, obesity, liver and kidney diseases, pulmonary conditions, and neurological and genetic disorders. Its approved product, REDEMPLO (plozasiran), is used with diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome. Arrowhead earns money from commercializing its own medicines and through license and collaboration agreements for programs it does not plan to commercialize independently. These arrangements may include development and commercialization responsibilities for partners, co-commercialization and profit sharing, or royalties. Arrowhead is headquartered in Pasadena, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ARWR in the last 30 days.
See all $ARWR insider activity →RBC Capital maintained its Outperform rating and $100 price target for Arrowhead Pharma, implying 112.1% upside from the Nov 12 close of $47.15. Recent analyst price targets range from $96 to $120.
Stifel reduced its price target for Arrowhead Pharmaceuticals (ARWR) to $96 from $104, citing weaker-than-expected Tryngolza launch results. The stock has fallen 19% in a week, trading at $47.15. Despite this, Arrowhead and partner Ionis maintain confidence in peak sales targets. The company reported a wider loss for fiscal 2026, but revenue of $450.8 million exceeded expectations, driven by REDEMPLO launch momentum.
Arrowhead Pharmaceuticals reported 2026 fiscal year-end results, highlighting growth in REDEMPLO prescriptions and regulatory approvals in the U.S. and Europe. The company also announced progress in its plozasiran program, including FDA STAR program entry and positive clinical trial results. Additionally, Arrowhead presented promising data for ARO-DIMER-PA and ARO-MAPT, its investigational RNAi therapeutics.
Over the past 7 days, AlphAI's AI scored 23 news stories mentioning ARWR (ARROWHEAD PHARMACEUTICALS, INC.). Coverage has skewed bearish: 6 bullish, 2 neutral, and 15 bearish.
Recent ARWR coverage spans financial news, earnings and technology.
Analyst maintains bullish stance and price target, suggesting continued positive sentiment.
Analyst downgrade suggests near‑term downside pressure on ARWR.
Strong commercial traction and pivotal trial success may lift the stock.
Positive trial outcomes and regulatory milestones suggest near‑term revenue upside and share price appreciation.
Mixed trial data triggered a sharp sell‑off, but analysts remain bullish with buy ratings and $120‑$126 price targets.
AlphAI scores every news story that mentions ARWR with an AI model for sentiment and relevance, and aggregates insider trades from ARROWHEAD PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RBC Capital maintained its Outperform rating and $100 price target for Arrowhead Pharma, implying 112.1% upside from the Nov 12 close of $47.15. Recent analyst price targets range from $96 to $120.
Stifel reduced its price target for Arrowhead Pharmaceuticals (ARWR) to $96 from $104, citing weaker-than-expected Tryngolza launch results. The stock has fallen 19% in a week, trading at $47.15. Despite this, Arrowhead and partner Ionis maintain confidence in peak sales targets. The company reported a wider loss for fiscal 2026, but revenue of $450.8 million exceeded expectations, driven by REDEMPLO launch momentum.
Arrowhead Pharmaceuticals reported 2026 fiscal year-end results, highlighting growth in REDEMPLO prescriptions and regulatory approvals in the U.S. and Europe. The company also announced progress in its plozasiran program, including FDA STAR program entry and positive clinical trial results. Additionally, Arrowhead presented promising data for ARO-DIMER-PA and ARO-MAPT, its investigational RNAi therapeutics.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 PRESS RELEASE Nov. 12, 2026 Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results Conference Call and Webcast Today, November 12, 2026, at 4:30 p.m. ET PASADENA, Calif., Nov. 12, 2026 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial
H.C. Wainwright reiterated a Buy rating and $120 price target for Arrowhead Pharmaceuticals (ARWR) after positive data presentations at the American Heart Association Scientific Sessions. The data included results for Plozasiran and ARO-DIMER-PA, showing efficacy but some side effects. ARWR shares fell 15.3% on November 9, contrasting with gains in biotech ETFs.
Piper Sandler maintained an Overweight rating and $126 price target for Arrowhead Pharmaceuticals (ARWR) after positive Phase I/IIa data on ARO-DIMER-PA. The stock fell 17% after Novartis' trial failure. Arrowhead plans a supplemental drug application for REDEMPLO by year-end. Analysts cite its pipeline and strong balance sheet as reasons for optimism, with pro forma cash of $1.74B and a current ratio of 5.9. Earnings are due November 12.
Arrowhead Pharmaceuticals' plozasiran showed sustained efficacy and safety in treating familial chylomicronemia syndrome (FCS) over 36 months, according to the PALISADE extension trial presented at the AHA Scientific Sessions 2026. The study reported an 80% reduction in fasting triglycerides (TG) and an 84% reduction in ApoC3 levels, with a favorable safety profile. The trial enrolled 75 patients, with 65 entering the open-label extension.
Five mid-cap biotechs are highlighted with upcoming catalysts. Cytokinetics (CYTK) awaits an FDA decision on Nov 14. Arrowhead (ARWR) reports earnings on Nov 12, while Ionis (IONS) saw a post-earnings sell-off. Crispr (CRSP) and Viking (VKTX) have undated catalysts. CYTK's Q3 revenue was $47.6M, beating estimates. ARWR's consensus EPS is -1.55, and IONS beat EPS and revenue estimates. CRSP showed Phase 1b data, and VKTX's next earnings are tentatively Feb 10, 2027.
Arrowhead Pharmaceuticals' stock fell 15.4% to $49.21 on Monday, with a market value of about $7 billion. The decline followed Ionis Pharmaceuticals' reduced sales forecast for its competing triglyceride drug, Tryngolza, which saw a 27% drop in Ionis' shares. Arrowhead's plozasiran (Redemplo) is positioned against Tryngolza, with Arrowhead citing its quarterly dosing and safety profile as advantages. Arrowhead has not issued a statement explaining the decline.
Arrowhead's plozasiran reduced acute pancreatitis events by 91% in severe hypertriglyceridemia patients with recent attacks. ARO-DIMER-PA showed LDL-C reductions up to 65% and triglyceride reductions up to 78%. Data presented at AHA Scientific Sessions 2026.
